| Identification | Back Directory | [Name]
Fosciclopirox | [CAS]
1380539-06-9 | [Synonyms]
CPX-POM
Fosciclopirox
γ-secretase,Fosciclopirox,Gamma secretase,Inhibitor,inhibit | [Molecular Formula]
C13H20NO6P | [MDL Number]
MFCD34578234 | [MOL File]
1380539-06-9.mol | [Molecular Weight]
317.27 |
| Chemical Properties | Back Directory | [Boiling point ]
484.8±55.0 °C(Predicted) | [density ]
1.38±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (315.19 mM; Need ultrasonic) | [form ]
Solid | [pka]
1.68±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Fosciclopirox suppresses growth of urothelial cancer by targeting the γ-secretase complex. Fosciclopirox selectively delivers the active metabolite, Ciclopirox (CPX), to the entire urinary tract[1][2]. Ciclopirox has anticancer activity in a number of solid and hematologic malignancies. | [storage]
Store at -20°C | [References]
[1] Weir SJ, et al. Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex. Cell Death Dis. 2021 May 31;12(6):562. DOI:10.1038/s41419-021-03836-z
[2] Weir SJ, Wood R, Schorno K, Brinker AE, Ramamoorthy P, Heppert K, Rajewski L, Tanol M, Ham T, McKenna MJ, McCulloch W, Dalton M, Reed GA, Jensen RA, Baltezor MJ, Anant S, Taylor JA 3rd. Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs. J Pharmacol Exp Ther. 2019 Aug;370(2):148-159. DOI:10.1124/jpet.119.257972 |
|
|